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Mutations in PIGU Impair the Function of the GPI
Transamidase Complex, Causing Severe Intellectual
Disability, Epilepsy, and Brain Anomalies
Alexej Knaus,1,9,* Fanny Kortu¨m,2,9 Tjitske Kleefstra,3,9 Asbjørg Stray-Pedersen,4,9 Dejan ukic,1
Yoshiko Murakami,5 Thorsten Gerstner,6 Hans van Bokhoven,3 Zafar Iqbal,3,7 Denise Horn,8
Taroh Kinoshita,5 Maja Hempel,2,10 and Peter M. Krawitz1,10
The glycosylphosphatidylinositol (GPI) anchor links over 150 proteins to the cell surface and is present on every cell type. Many of these
proteins play crucial roles in neuronal development and function. Mutations in 18 of the 29 genes implicated in the biosynthesis of the
GPI anchor have been identified as the cause of GPI biosynthesis deficiencies (GPIBDs) in humans. GPIBDs are associated with intellec-
tual disability and seizures as their cardinal features. An essential component of the GPI transamidase complex is PIGU, along with PIGK,
PIGS, PIGT, andGPAA1, all of which link GPI-anchored proteins (GPI-APs) onto the GPI anchor in the endoplasmic reticulum (ER). Here,
we report two homozygous missense mutations (c.209T>A [p.Ile70Lys] and c.1149C>A [p.Asn383Lys]) in five individuals from three
unrelated families. All individuals presented with global developmental delay, severe-to-profound intellectual disability, muscular hypo-
tonia, seizures, brain anomalies, scoliosis, andmild facial dysmorphism. Usingmulticolor flow cytometry, we determined a characteristic
profile for GPI transamidase deficiency. On granulocytes this profile consisted of reduced cell-surface expression of fluorescein-labeled
proaerolysin (FLAER), CD16, and CD24, but not of CD55 and CD59; additionally, B cells showed an increased expression of free GPI
anchors determined by T5 antibody. Moreover, computer-assisted facial analysis of different GPIBDs revealed a characteristic facial
gestalt shared among individuals with mutations in PIGU and GPAA1. Our findings improve our understanding of the role of the GPI
transamidase complex in the development of nervous and skeletal systems and expand the clinical spectrum of disorders belonging
to the group of inherited GPI-anchor deficiencies.
The linkage of over 150 different proteins to the cell sur-
face is facilitated by the glycosylphosphatidylinositol
(GPI) anchor. GPI-anchored proteins (GPI-APs) play impor-
tant roles in embryogenesis, neurogenesis, signal transduc-
tion, and various other biological processes in all tissues of
the human body.1,2 Hence, biosynthesis, modification,
and transfer of the GPI anchor to the proteins are highly
conserved processes mediated by at least 31 genes. The
GPI transamidase is a heteropentameric complex (encoded
by PIGK [MIM: 605087], PIGS [MIM: 610271], PIGT [MIM:
610272], GPAA1 [MIM: 603048], and PIGU [MIM: 608528,
RefSeq accession number NM_080476.4]) that mediates
the transfer of the protein to the GPI anchor in the endo-
plasmatic reticulum (ER).
A recent protein-sequence analysis study showed that
the ten predicted transmembrane domains (TMs) of
PIGU share high sequence similarity with the mannosyl-
transferases PIGM, PIGV, PIGB, and PIGZ but lack
functionally important motifs.3 These ten TMs were antic-
ipated to bind the GPI lipid anchor. In addition, it was
determined that PIGU is the last component that associ-
ates with the core protein complex of the GPI transamidase
formed by PIGT, PIGS, PIGK, and GPAA1.4 Therefore, the
presumed molecular function of PIGU is the presentation
of the GPI lipid anchor to the transamidase complex in a
productive conformation.3
Mutations in three genesof theGPI transamidase complex
havebeenassociatedwithhumandisease. Severe intellectual
disability, global developmental delay, muscular hypotonia,
seizures, andcerebellar atrophyweredescribed in individuals
withGPAA1 (GPIBD15 [MIM:617810])5 andPIGTmutations
(GPIBD7 or multiple congenital anomalies-hypotonia-sei-
zures syndrome 3 [MCAHS3 (MIM: 615398)]);6 PIGS defi-
ciency leads to severe global developmental delay, seizures,
hypotonia, ataxia, and dysmorphic facial features (GPIBD18
[MIM: 618143]).7 Here, we describe five individuals from
three unrelated families with rare biallelic missense muta-
tions in PIGU presenting with global developmental delay,
severe-to-profound intellectual disability, muscular hypoto-
nia, seizures, brain anomalies, scoliosis, and mild facial dys-
morphism consistent with GPI biosynthesis deficiencies
(GPIBDs).8,9 We provide clinical and functional evidence
for a form of a severe autosomal-recessive GPIBD caused by
pathogenic mutations in PIGU.
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Proband P-1 was the first daughter of healthy first-degree
cousins (family 1) from Turkey; she was born at term after
an uncomplicated pregnancy. Myoclonic seizures occurred
within the first months and responded poorly to treat-
ment. At the age of 7 months, a global developmental
delay and severe muscular hypotonia with reduced sponta-
neous movements were noted. Magnetic resonance imag-
ing (MRI) of her brain revealed delayed myelination and
a small focal periventricular gliosis on the left side. Persis-
tent focal myoclonic seizures, occurrence of generalized
myoclonic-tonic seizures, and spasticity in all limbs led
to a slow regression and loss of all achieved skills. Repeated
MRI of her brain at the ages of 4 years and 12 years showed
atrophy of the white matter. When we saw her at the age of
19 years, we saw a profoundly disabled young woman with
poor interaction and without speech; she was wheelchair
bound and fed by a gastric tube. X-rays of her spine re-
vealed osteopenia and scoliosis (See case reports in Supple-
mental Data).
Her brother (P-2) was the third child of family 1 and was
born at term after a normal pregnancy. At age 7 weeks, the
first generalized seizure occurred, followed by a series of
therapy-resistant frequent focal myoclonic seizures. He
showed profound developmental delay, muscular hypoto-
nia, and poor eye contact. Visual evoked cortical potentials
(VECPs) were absent on the right eye and diminished on
the left eye. An electrocardiogram (ECG) revealed an
incomplete right bundle branch block (RBBB), and echo-
cardiography showed an atrial septal defect (ASD) type II.
At the age of 4 years, he had supraventricular tachycardia
followed by further episodes requiring hospitalization
and cardioversion. When we saw him at the age of 12
years, we saw a wheelchair-bound boy with profound
intellectual disability, poor interaction, no speech, and se-
vere scoliosis and who was fed by a percutaneous endo-
scopic gastrostomy (PEG) tube.
P-3 is the first son of non-consanguineous healthy par-
ents of European descent (family 2); he was born at
42 weeks of gestation after a normal pregnancy. He was hy-
potonic but without feeding problems. At the age of
11 months, he developed mainly myoclonic seizures and
absences that were treated but not fully controlled. A brain
MRI showed progressive cerebellar atrophy. At the age of 6
years, he showed a dysmetric movement disorder and pro-
found developmental delay. Scoliosis was surgically cor-
rected at the age of 17 years.
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Figure 1. Pedigrees of the Families 1, 2,
and 3 with the Mutations in PIGU
The consanguineous parents from family 1
are of Turkish descent. Family 2 is from the
Netherlands. Family 3 is from Norway.
His brother (P-4) was born at term
after a normal pregnancy. He was hy-
potonic. Brain MRI performed at the
age of 4 months showed frontal atro-
phy and a Dandy Walker variant. His global development
was profoundly delayed; he was able to speak two-to-
three-word sentences and to walk a few steps at age of 5
years. At the age of 6 years, myoclonic epilepsy developed;
this is now well controlled. An MRI done at this age
showed progressive vermis hypoplasia. At his current age
of 12 years, he is able to walk independently for short dis-
tances and to speak sentences of a few words. He has also
developed scoliosis.
P-5 was the first daughter born to non-consanguineous
healthy parents from Norway (family 3); she was born at
42 weeks of gestation after a normal pregnancy. She was
hypotonic and had feeding problems. A brain MRI per-
formed at the age of 10 months showed a thin corpus cal-
losum and an enhanced ventricular system without signs
of hydrocephalus. Her global development was profoundly
delayed. Focal myoclonic seizures started at 3.5 years of age
andwere responding well to therapy.Whenwe saw her at 5
years of age, she was a wheelchair-bound girl who spoke
only few words and had impaired cortical vision. She was
considered for a surgical correction of her scoliosis.
The individuals in this study were identified via the
MatchmakerExchange platform10 using data that origi-
nated from the University Medical Center Hamburg-Ep-
pendorf, Germany (family 1, P-1 and P-2), the Radboud
University Hospital, Nijmegen, the Netherlands, (family 2,
P-3 and P-4) and the Norwegian National Unit for
Newborn Screening, Division of Pediatric and Adolescent
Medicine, Oslo, Norway (family 3, P-5). All samples were
obtained after written informed consent was given by
the guardians of the affected individuals. The study was
performed in accordance with the Declaration of Helsinki
protocols and approved by the ethics committees of the
respective institutions.
Whole-exome sequencing (WES) revealed two rare ho-
mozygous variants in PIGU (GenBank: NM_080476.4):
c.209T>A (p.Ile70Lys), exon 3 in the two affected siblings
(P-1 and P-2) of family 1, and c.1149C>A (p.Asn383Lys),
exon 11 in families 2 and 3 (Figures 1 and 2A). Sanger
sequencing confirmed biparental inheritance of the vari-
ants in all families; pedigrees and genotypes are shown
in Figure 1. The variant c.209T>A (CADD score 25.9) has
not been observed in gnomAD,11 while c.1149C>A
(CADD score 26.5) has been observed only in a heterozy-
gous state, in individuals from a European population,
and with an allele frequency of 7/277194. Both variants
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were predicted to be pathogenic by MutationTaster,12
UMD Predictor,13 SIFT,14 and PolyPhen2.14 The exchange
of the hydrophobic amino acid isoleucine at position 70
to a hydrophilic lysine was predicted to cause a conforma-
tional change of the first ER luminal domain between TM1
and TM2 (Grantham score 102). The exchange of the
amino acid asparagine to lysine at position 383 is also posi-
tioned in an ER luminal domain before TM10 (Grantham
score 94) (Figures 2B and 3C).
To assess the functional implications of themissense var-
iants in PIGU for the GPI anchoring process, we performed
flow cytometry on peripheral blood samples collected in
CytoChex blood collection tubes (BCTs). For multicolor
flow cytometry, cells were stained with fluorescently
labeled antibodies against GPI-APs (CD16, CD24, CD55,
and CD59), as well as with fluorescein-labeled proaerolysin
(FLAER), which binds to the GPI anchor itself. Use of
the T5 4E10 antibody allowed detection of free GPI
anchors.15–18
Relative reduction of GPI-AP was calculated as a ratio of
the staining index (SI) of an affected individual to the SIs of
healthy parents and healthy unrelated controls. It is note-
worthy that there were only subtle differences in GPI-AP
staining between heterozygous carriers of pathogenic mu-
tations (parents) and unrelated healthy controls.
As revealed by reduced expression of FLAER, the relative
expression of GPI-APs CD16 and CD24 was significantly
reduced on granulolcytes compared to controls. But
CD55 expression was not significantly altered and CD59
expression was only slightly increased in three out of
four individuals with mutations in PIGU compared to con-
trols. (Figure 3). However, CD55 expression was not altered
from that of controls, whereas CD59 expression was higher
than that in controls in three out of four individuals with
mutations in PIGU. This characteristic pattern of marker
staining was observed in some individuals with mutations
in PIGT, but this was not addressed by the authors.19,20 The
deficiency of the GPI transamidase in linking GPI-APs to
the GPI anchor results in an abundance of free GPI on
the cell surface. This can be assessed by the T5 antibody,
which binds to the N-acetyl-galactoseamine side branch
at the first mannose of the GPI anchor.16,21 Compared to
that of controls, the MFI for T5 of affected individuals’
B cells (for monocytes and granulocytes, data not shown)
showed an increase of up to 3-fold (Figure 3). Thus, we
conclude that the identified missense mutations in PIGU
reduce the function of the GPI transamidase complex
and lead to accumulation of free GPI anchor on the cell
surface. Functional validation of the p.Asn383Lys variant
was performed in a CHO cell line deficient for PIGU.
Expression of GPI-APs was rescued less efficiently by tran-
sient expression of the p.Asn383Lys mutant than by
wild-type PIGU (Figure S3).
In order to analyze the phenotypic spectrum of the GPI
transamidase deficiency and compare it to other GPIBDs,
we conducted a systematic review of the phenotypic fea-
tures of the most prevalent GPIBDs from the literature
and additional cases with molecularly diagnosed GPIBDs
(unpublished data). Therefore, we included individuals
with mutations in PIGT (n ¼ 26), GPAA1 (n ¼ 10), PIGU
(n ¼ 5), and PIGS (n ¼ 4, excluding two fetuses) for the
GPI transamidase deficiencies; PIGV (n ¼ 26) and PGAP3
(n ¼ 28) for two types of hyperphosphatasia with mental
retardation syndrome (HPMRS), HPMRS1 (MIM: 239300)
A
B
C
Figure 2. Position of Mutations in PIGU Gene and Protein
(A) Exon-intron structure and mutational landscape of PIGU.
(B) Conservation (black to gray shading) of PIGU protein sequence over multiple species and prediction of transmembrane (red arrows)
domains.
(C) Transmembrane domain structure and location of missense variants in PIGU.
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and HPMRS3 (MIM: 615716), respectively; and PIGN
(n ¼ 30; MIM: 606097) and PIGA (n ¼ 54; MIM: 311770)
for two types of multiple congenital anomalies-hypoto-
nia-seizures syndrome (MCAHS), MCAHS1 (MIM:
614080) and MCAHS3 (MIM: 300868), respectively. We
grouped the reported clinical features of the cases in the
following 16 feature classes: developmental delay and/or
intellectual disability, muscular hypotonia, seizures, cere-
bellar anomalies (cerebellar hypoplasia, vermis hypoplasia,
etc.), anomalies of the corpus callosum (CC)(including
thin CC or hypoplasia of the CC), hearing impairment
(including hearing loss), cortical visual impairment
Figure 3. Relative Cell Surface Expression of GPI-APs on Granulocytes and B Cells
On granulocytes of affected individuals (P-1, P-3, P-4, and P-5) a significant relative reduction of cell surface expression of FLEAR, CD16,
and CD24 was observed compared to controls. But expression of CD55 and CD59 was not significantly altered on granulocytes. An
increased expression of free GPI anchors was detected based on the presence of T5 antibody on B cells in affected individuals compared
to controls. Values represent mean þ SD. Error bars: n ¼ 3 (parents and one healthy unrelated control), significance was verified by
Student’s t-test, ns ¼ not significant, *p<0.05, **p<0.01.
Figure 4. Clustering and Heatmap of
Feature Frequency per Gene
Genes of the HPMRS disease entity are
highlighted in blue, MCAHS genes in
green.
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(including cortical blindness), impairment of the eyes
(including strabism, nystagmus, and severe hyper- or
myopia), cleft palate, genitourinary anomalies (including
malformations of kidneys, urinary tract, or genitalia), heart
defects (including ASD and patent ductus arteriosus), scoli-
osis, osteopenia (including osteoporosis), gastrointestinal
anomalies (Hirschsprung disease and megacolon), brachy-
phalangy (including hypoplastic nails and short fingers or
fingertips), and hyperphosphatasia. We counted the
phenotypic features and divided by the number of cases
that were assessed for each particular feature to determine
the feature frequency per gene. The feature frequencies
were plotted in a two-dimensional heatmap, and clus-
tering was performed on the basis of Euclidian distance
as a measure of similarity.
The feature analysis revealed a high similarity among indi-
vidualswithmutatedgenesof theGPI transamidasecomplex
(GPAA1, PIGT, and PIGU); their shared features were cere-
bellar anomalies, impairmentsof eyes, andosteopenia.How-
ever, osteopenia might be related to the inactivity of these
severely disabled people. Scoliosis was identified in nearly
all PIGU-deficient individuals and is probably a typical clin-
ical feature ofPIGU-associatedGPIBD. So far, hearing impair-
ment and hyperphosphatasia have not been described in
individualswithGPI transamidasedeficiency.Genitourinary
malformations and heart defects without hyperphosphata-
sia and cleft palate were frequent in individuals with PIGT,
PIGN, and PIGA mutations and are therefore considered
characteristic for the MCAHS disease entity. Hypophospha-
tasia and cleft palate (together with brachyphalangy) were
the most common features in individuals with PIGV and
PGAP3 mutations, and these features represent the major
symptoms in HPMRS. The dichotomy between the HPMRS
and MCAHS characteristic phenotypic features is visualized
in the twobranches of the dendrogram inFigure 4.However,
delineation of these disease entities based on the frequency
of phenotypic features is challenging because of the
broad phenotypic variability of MCAHS and also because
elevated amounts of serum alkaline phosphatase (ALP) is
not restricted to HPMRS. The major discriminatory
features between HPMRS and other GPIBDs are increased
levels of ALP in combination with cleft palate and
brachytelephalangy. Genitourinary malformations were
described in most individuals with PIGV deficiency, while
anomalies of the corpus callosum were identified in most
PGAP3-affected individuals. Except for in the case of brain
Table 1. Comparison of the Clinical Features of Individuals with Mutations in PIGU versus Previously Reported Individuals with Mutations
in PIGT, PIGS, and GPAA1
PIGU P-1 PIGU P-2 PIGU P-3 PIGU P-4 PIGU P-5 PIGT (n ¼ 13)19,20,22–25 PIGS (n ¼ 6)7 GPAA1 (n ¼ 10)5
Age 19 years 12 years 17 years 12 years 5 years 11 months to 12 years prenatal to 5.5
years
4 to 30 years
Measurements microcephaly normal Normal normal macrocephaly microcephaly (2/9, 3 ND) microcephaly
(2/4, 2 ND)
short stature (5/10),
microcephaly (1/
10)
Alkaline
phosphatase
normal normal Normal normal normal low 8/13 normal (6/6) normal (10/10)
Developmental
delay
profound profound Profound severe profound profound (13/13) yes (4/4, 2 ND) mild to moderate
(10/10)
Intellectual
disability
profound profound Profound severe profound profound (13/13) yes (4/4, 2 ND) mild to moderate
(10/10)
Muscular
hypotonia
yes yes Yes yes yes, severe yes (13/13) yes (4/4, 2 ND) yes (10/10)
Spasticity yes yes no no no ND no yes (4/9, 1 ND)
Seizures yes yes Yes yes yes yes (13/13) yes (4/4, 2 ND) yes (7/10)
Cerebral
atrophy
global global no frontal mild global yes (9/11, 2 ND) yes (2/4, 2 ND) no
Cerebellar
hypoplasia
progressive no progressive progressive no yes (9/11) yes (4/4, 2 ND) yes (9/10)
Cortical
blindness
yes yes no no yes yes (9/9) yes (3/4) yes (1/10)
Strabismus yes yes yes yes yes yes (9/9) ND ND
Nystagmus no no no no yes ND yes (3/4) yes (7/10)
Scoliosis severe severe severe yes severe yes (5/7) yes (1/4) mild (n ¼ 1)
Osteopenia yes ND ND ND ND yes (7/9) ND yes (8/10)
other slender bones no no no no no brachydactyly
(4/6)
no
‘‘ND’’ indicates not documented.
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anomalies, malformations were more prevalent in individ-
uals withHPMRS than in individuals with theMCAHS spec-
trum,whereas in the latter group, ahigher frequencyofbrain
abnormalities has been documented. Cerebellar anomalies
were frequent in all GPIBDs except HPMRS. All individuals
with GPIBDs were affected by developmental delay and/or
intellectual disability, muscular hypotonia, and seizures. A
comparison of the phenotypic features of all diagnosed indi-
viduals with mutations in PIGU versus those of individuals
with mutations in GPAA1, PIGT, and PIGS is presented in
Table 1. More comprehensive clinical descriptions are listed
in the Supplemental Data.
A characteristic facial gestalt was observed formany indi-
viduals with GPIBDs. In a recent study, the facial features
of individuals with GPIBDs were analyzed with FDNA’s
DeepGestalt neural network.26,27 However, the five indi-
viduals with PIGUmutations presented with only very sub-
tle characteristic facial features. Therefore, we applied an
approach with higher sensitivity and specificity to analyze
genotype-phenotype correlations. Here, we used data from
previously published cases5,25,26 as well as unpublished
facial images of individuals with mutations in GPAA1,
PIGA, PIGN, PGAP3, and PIGT to compare the facial gestalt
to that of individuals with mutations in PIGU (n ¼ 5). We
chose PIGA (n ¼ 25), PIGN (n ¼ 15), PIGT (n ¼ 13), PIGV
(n ¼ 24), and PGAP3 (n ¼ 25) (unpublished data) as the
most prevalent GPIBDs and we chose GPAA1 (n ¼ 5) as
another gene of the GPI transamidase complex. In total,
112 molecularly confirmed cases were processed. Informed
Figure 5. Pairwise Distances of Gene Cen-
troids of Facial Image Embeddings from
GPIBD Cases
The FaceNet-based image analysis of
112 molecularly diagnosed GPIBD cases
achieved a gene-level classification accuracy
of 62%.
consent was obtained from all families
and was approved by the institutional
review boards at the relevant institu-
tions. Embeddings of facial images in
a 128-dimensional space were calcu-
lated via a FaceNet-based approach.28
A pairwise distance comparison of the
centroids of each gene cohort was
then performed and clustered on the
basis of Euclidian distances as the mea-
sure of similarity (Figure 5). In this
approach, we achieved a gene-level
classification accuracy of 62%, which
is significantly better than random
chance (1/7 ¼ 14.3%).
As described previously by Knaus
et al.,26 individuals with PGAP3 and
PIGVmutations shared a characteristic
facial gestalt and represented the
HPMRS branch in the dendrogram (Figure 5). Also, individ-
uals with MCAHS (PIGN, PIGA, and PIGT) shared facial
similarities. As a result of shared facial similarities, the
five individuals with PIGU mutations and the five with
GPAA1 mutations formed a GPI transamidase branch in
the dendrogram (Figure 5). It is notable that in our anal-
ysis, the facial gestalt of individuals with PIGT mutations
shows a high level of dissimilarity to those individuals
with PIGU (distance 2.49) and GPAA1 (3.00) mutations.
Discussion
Here, we describe a type of the autosomal-recessive GPIBD
caused by bi-allelic mutations in PIGU. Deep phenotyping
of the five affected individuals and of published cases with
GPIBDs revealed shared phenotypic features in individuals
with mutations in genes of the GPI transamidase complex.
Impairment of the nervous system (cortical impairment of
vision, cerebellar anomalies, and anomalies of the corpus
callosum) with severe motor delay and associated skeletal
anomalies (scoliosis and osteopenia) were characteristic
in people with GPI transamidase deficiency. Intellectual
disability or developmental delay, muscular hypotonia,
and seizures are shared features among all individuals
with GPIBD.
Computer-assisted facial analysis supported our assump-
tion of facial similarities among individuals with GPI trans-
amidase deficiency (with mutations in PIGU and GPAA1),
400 The American Journal of Human Genetics 105, 395–402, August 1, 2019
individuals with HPMRS (with mutations in PIGV and
PGAP3), and individuals with MCAHS (with mutations in
PIGA, PIGN, and PIGT). We show that the effectiveness of
computer-assisted gestalt analysis has a high potential to
draw conclusions on the disturbed gene or protein com-
plex in individuals with GPIBDs and probably beyond.
We were able to achieve a better-than-random accuracy
of 62% in predicting the affected gene in a pathway disor-
der solely from facial images, in spite of the unbalanced co-
horts with few cases and different ethnic backgrounds.
Computer-readable information contained in human
face permitted classification of phenotypes into disease en-
tities or syndrome families,26,29–31 and this classification
could in turn be used to predict affected genes or identify
novel disease genes in known pathways.32 Moreover, the
combination of computer-assisted facial analysis and
deep phenotyping might not only be helpful in disease-
gene identification but could also improve variant predic-
tion in exome or genome data analysis.
The phenotypic features resulting from functional impair-
ment of PIGUwere corroborated by flow-cytometric analysis
of GPI-AP expression and identification of free GPI anchors
on the cell surfaces of blood cells. A biochemical discrimina-
tion of GPI transamidase deficiencies and other GPIBDs is
possible throughuse of theT54E10antibody.18More impor-
tantly, in a functional workup of suspected GPIBDs, a multi-
color flow cytometry panel is necessary in order to avoid
missingpotentialGPIBDcases inwhichexpressionof several
GPImarkers isnot reduced.Here,wedefineamulticolor flow
cytometry panel (consisting of the GPI markers FLAER,
CD16, CD24, CD55, CD59, and T5) to identify a character-
istic profile of GPI marker expression in GPI transamidase
deficiency. A more detailed and standardized analysis of
GPI-AP expression of molecularly confirmed GPIBD cases
might potentially identify more gene-specific or protein-
complex-specific flow-cytometry profiles.
In conclusion, application of deep phenotyping in com-
bination with computer-assisted facial analysis can sup-
port the diagnosis of suspected GPIBD cases where access
to sequencing or flow cytometry is limited. Furthermore,
this approach can help researchers to interpret variants
of unknown clinical significance in GPIBD-associated
genes. The identification of more individuals with GPIBDs
and deep phenotyping thereof might facilitate prognosti-
cation of the condition on the basis of the mutated gene.
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